Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials
Open Access
- 18 October 2025
- journal article
- review article
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 100 (6) , 501210
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo NodularisJAMA Dermatology, 2025
- A systematic review of interleukin-31 inhibitors in the treatment of prurigo nodularisInflammopharmacology, 2024
- Chronic Prurigo Including Prurigo Nodularis: New Insights and TreatmentsAmerican Journal of Clinical Dermatology, 2023
- Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyeClinicalMedicine, 2023
- Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential TreatmentsDermatology and Therapy, 2022
- Nemolizumab: First ApprovalDrugs, 2022
- Nemolizumab: un innovador tratamiento biológico para el control de la interleuquina 31 (IL-31) clave en la dermatitis atópica y el prurigo nodularActas Dermo-Sifiliograficas, 2022
- Prurigo nodularisJournal of the American Academy of Dermatology, 2020
- Prurigo nodularisJournal of the American Academy of Dermatology, 2020
- Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension studyJournal of Allergy and Clinical Immunology, 2018